Health & Science

Nurses say the pandemic has fueled a vicious cycle: short-staffing leads to unsafe conditions, which leads to many people leaving the profession.

Advisers to the Centers for Disease Control and Prevention have recommended a third dose of Pfizer's COVID-19 vaccine for people 65 and older, as well as others at a high risk

The Wolf Administration says a new plan can help the commonwealth reach its greenhouse gas reduction goals by 2050 and help avoid the worst effects of climate change.

Dr. Paul Offit on the COVID vaccines and his new book, "You Bet Your Life: From Blood Transfusions to Mass Vaccination, the Long and Risky History of Medical Innovation."

How to make the start of a new life as trauma-free as possible.

The U.S. has moved a step closer to offering booster doses of Pfizer’s COVID-19 vaccine to seniors and others at high risk from the virus.

So far, seven schools in New Jersey have reimplemented virtual instruction due to COVID outbreaks, and three of them remain remote.

As people remained indoors, stopped commuting to work or hopping on passenger jets, the birds increasingly flew into urban areas they had previously shunned.

The FDA itself still has to decide whether it agrees with its advisers’ recommendation and will authorize Pfizer boosters.

Philadelphia health officials have lowered the thresholds for when school buildings close because of positive COVID-19 cases. Here’s what you need to know.

The increasingly lethal turn has filled hospitals, complicated the start of the school year, delayed the return to offices and demoralized health care workers.

The pledge will come at the start of a virtual summit aimed at boosting commitments from other nations and the private sector.

Set to open in October, the clinic will offer blood draws for lab tests, X-rays, behavioral health care, checkups for adults and kids, and immunizations.

The COVID-19 crisis is by any measure a colossal tragedy in its own right, especially given the incredible advances in scientific knowledge since 1918.

J&J shared data from its Phase 3 trial of the company's booster shot on Tuesday. The data showed a booster shot at six months provided a 12-fold increase in antibodies.